Clinical Trials Logo

Carcinoma, Hepatocellular clinical trials

View clinical trials related to Carcinoma, Hepatocellular.

Filter by:

NCT ID: NCT01963949 Withdrawn - Clinical trials for Hepatocellular Carcinoma

Prospective, Observational Study of Biomarkers in Liver Cancer - Identification of Actionable Events

Start date: October 2013
Phase: N/A
Study type: Observational [Patient Registry]

To collect tumor tissue from patients with liver masses suspicious for primary liver cancer. The research biopsy will be used to identify biomarkers in future studies.

NCT ID: NCT01956864 Withdrawn - Clinical trials for Hepatocellular Carcinoma

Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer

Start date: September 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of a high dose of vitamin D (VD) in patients with cirrhosis. The investigator hypothesizes that high dose VD will be safe and well-tolerated in adults with cirrhosis, and will inhibit the inflammatory and proliferative events that cause progression of cirrhosis to hepatocellular carcinoma.

NCT ID: NCT01953406 Withdrawn - Clinical trials for Hepatocellular Carcinoma

The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma

Start date: November 2015
Phase: Phase 2
Study type: Interventional

The aim of this study is to evaluate the efficacy of 5-fluorouracil + Mitomycin for the patients with pulmonary metastasis of hepatocellular carcinoma who had progressive disease with sorafenib.

NCT ID: NCT01923233 Withdrawn - Clinical trials for Hepatocellular Carcinoma

In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer

Start date: November 2014
Phase: Phase 1/Phase 2
Study type: Interventional

This study is an individualized anti-cancer vaccine protocol where the vaccination occurs inside of the body. To create the vaccine, a tumor lesion is selected and caused to die by a process called "Radiofrequency Ablation" or RFA. RFA causes the tumor to release its internal contents to the surrounding environment, such contents include tumor-specific antigens. Immune cells respond to the tissue damage and take-up these tumor antigens. The injection of the experimental cell drug, AlloStim(TM) into the lesion is designed to cause the responding cells to signal the immune system of the danger of the tumor, creating tumor-specific immunity.

NCT ID: NCT01875549 Withdrawn - Clinical trials for Hepatocellular Carcinoma

Comparison Between Unilateral Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction to Use a LCD Stent

Start date: May 2013
Phase: N/A
Study type: Interventional

Internal biliary drainage is an useful method for a control of jaundice and cholangitis to patients who had a malignant hilar obstruction due to hepatocellular carcinoma, cholangiocarcinoma, gall bladder cancer or metastatic lymphadenopathy. Bilateral biliary drainage is more physiologic but technically difficult to compared with unilateral biliary drainage specially related to conformability and flexibility between using stents. There are no prospective clinical trials compared with these internal biliary drainage methods in hilar malignant obstruction using metal stent. Therefore, the investigators want to compare the clinical outcome of two method: Unilateral biliary stent and Bilateral biliary stent

NCT ID: NCT01857726 Withdrawn - Clinical trials for Hepatocellular Carcinoma

Comparison of TACE Versus TACE/TACI Combination in Advanced Hepatocellular Carcinoma With Portal Vein Invasion

Start date: July 2013
Phase: N/A
Study type: Interventional

The aim of this study is to compare the efficacy of transarterial chemoembolization with adriamycin to transarterial chemoembolization with adriamycin/transarterial chemoinfusion with cisplatin combination in advanced hepatocellular carcinoma with portal vein invasion.

NCT ID: NCT01831037 Withdrawn - Chronic Hepatitis B Clinical Trials

The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study

ROLFH
Start date: July 2015
Phase: N/A
Study type: Observational

This study aims to demonstrate that patients with chronic hepatitis C (CHC) and B (CHB) experiencing regression of liver cirrhosis after effective antiviral therapy have decreased risk for hepatocellular carcinoma (HCC). Primary aim is to determine the incidence of HCC in patients with cirrhosis secondary to CHC and CHB, after treatment is provided, and to identify the magnitude of the decreased risk for HCC in patients experiencing regression of fibrosis. As a secondary aim, environmental risk factors for HCC development will be sought, in order to determine a subset of patients in whom it will be safe to stop surveillance.

NCT ID: NCT01801163 Withdrawn - Clinical trials for Hepatocellular Carcinoma

A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC)

Start date: February 2012
Phase: Phase 1
Study type: Interventional

This is a research study of a radiation treatment called stereotactic body radiotherapy (SBRT) plus a medicine called sorafenib. The purpose of this study is to evaluate the safety of SBRT plus Sorafenib to see what effects (good and bad) it has on the treatment of liver cancer.

NCT ID: NCT01775280 Withdrawn - Clinical trials for Hepatocellular Carcinoma

Response of Hepatic Tumors to Radioembolization

RESRAD
Start date: October 2012
Phase: Phase 2
Study type: Interventional

The study enrolls patients with non-resectable or borderline resectable hepatocellular carcinoma (HCC), intraheaptic choalngiocarcinoma (IHCC) or colorectal cancer metastasis. Patients are not a candidates for liver transplantation and have only limited extrahepatic disease. All patients are treated with radioembolization. Primary endpoint is the percentage of patients that can be downstaged to resectability. Secondary endpoints are radiologic response to radioembolization,tissue response to radiomembolization and systemic immune response and intra-tumoral T-cell response to radioembolization. - Trial with radiotherapy

NCT ID: NCT01744639 Withdrawn - Liver Carcinoma Clinical Trials

Analysis of Body Composition in Patients With Hepatocellular Carcinoma in Radioablation

Start date: December 2012
Phase: N/A
Study type: Interventional

Number of shows: 20 patients Track: A month with three visiting Intervention: Nutritional assessment including anthropometry, bioelectrical impedance, biochemical tests, Psychometric Hepatic Encephalopathy Score and Critical Flicker Frequency.